Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma

NCT03400592 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Stomach Neoplasms

Interventions

DRUG: Irinotecan
DRUG: nimotuzumab

Sponsor

Peking University

Collaborators

[object Object]